Biomarin Pharmaceutical Inc (NASDAQ:BMRN) - Overview

Stock Report

Biomarin Pharmaceutical Inc BMRN

Last Price
$82.21

Day Change
-1.12|-1.34%

As of 02/12/2016
16:00:00 EST | USD
Minimum 15 Minutes Delay.

Last Close83.33
Day Range81.89 - 84.02
Mkt Cap14.14Bil
52-Wk Range62.12 - 107.56
Yield %-
ISINUS09061G1013
Volume1,142,525
P/E-28.06
P/S12.87
P/CF-45.36

Share Price

Financials
201320142015
More ...
Income Statement
Revenue548.49751.04889.90
Operating Income-156.01-92.89-110.70
Net Income-176.35-133.97-171.80
Basic EPS-1.28-0.92-1.07
Avg. Diluted Shares Outstanding138146160
Balance Sheet
Current Assets1,137.421,425.631,089.64
Non Current Assets1,111.801,064.822,639.73
Total Assets2,249.222,490.453,729.37
Current Liabilities183.27235.74445.46
Total Liabilities908.18962.561,328.52
Total Equity1,341.041,527.892,400.85
Cash Flow
Operating Cash Flow-59.63-73.54-221.69
Capital Expenditure-65.12-118.83-227.65
Free Cash Flow-124.76-192.37-449.34

In millions, except "Basic EPS". Currency is USD.

Company Profile

Biomarin Pharmaceutical Inc develops and commercializes pharmaceuticals for serious diseases and medical conditions. Its product portfolio is comprised of five product candidates Naglazyme, Kuvan, Aldurazyme, VIMIZIM and Firdapse.

Sector

Healthcare

Industry

Biotechnology

Stock Style

Mid-Growth

Fiscal Year Ends

December

Employees

2,158
Key Stats
More ...
Price/Earning TTM-28.54
Price/Book5.42
Price/Sales TTM13.83
Rev Growth (3 year avg)21.13
EPS Growth (3 year avg)-
Operating Margin % TTM-12.44
Net Margin % TTM-19.31
ROE TTM-8.75
Debt/Equity0.28
Dividends
PreviousLatest
More ...
Declared Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at Trafford House, Chester Road, Manchester M32 0RS. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2016 Morningstar. All rights reserved.